Financial Survey: Biorestorative Therapies (NASDAQ:BRTX) vs. Tenax Therapeutics (NASDAQ:TENX)

Tenax Therapeutics (NASDAQ:TENX) and Biorestorative Therapies (NASDAQ:BRTX) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, risk, institutional ownership, earnings, valuation and profitability.

Analyst Ratings

This is a summary of recent recommendations for Tenax Therapeutics and Biorestorative Therapies, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tenax Therapeutics	1	0	3	0	2.50
Biorestorative Therapies	1	0	0	0	1.00

Tenax Therapeutics currently has a consensus target price of $21.67, suggesting a potential upside of 46.59%. Given Tenax Therapeutics’ stronger consensus rating and higher probable upside, equities analysts plainly believe Tenax Therapeutics is more favorable than Biorestorative Therapies.

Institutional and Insider Ownership

1.7% of Tenax Therapeutics shares are held by institutional investors. Comparatively, 69.4% of Biorestorative Therapies shares are held by institutional investors. 3.1% of Tenax Therapeutics shares are held by insiders. Comparatively, 30.8% of Biorestorative Therapies shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Volatility and Risk

Tenax Therapeutics has a beta of 1.34, meaning that its stock price is 34% more volatile than the S&P 500. Comparatively, Biorestorative Therapies has a beta of 0.28, meaning that its stock price is 72% less volatile than the S&P 500.

Profitability

This table compares Tenax Therapeutics and Biorestorative Therapies’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Tenax Therapeutics	N/A	-43.24%	-41.52%
Biorestorative Therapies	-3,308.09%	-231.08%	-136.21%

Valuation & Earnings

This table compares Tenax Therapeutics and Biorestorative Therapies”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tenax Therapeutics	N/A	N/A	-$17.60 million	($1.13)	-13.08
Biorestorative Therapies	$400,000.00	25.64	-$8.98 million	($1.47)	-0.79

Biorestorative Therapies has higher revenue and earnings than Tenax Therapeutics. Tenax Therapeutics is trading at a lower price-to-earnings ratio than Biorestorative Therapies, indicating that it is currently the more affordable of the two stocks.

Summary

Tenax Therapeutics beats Biorestorative Therapies on 8 of the 13 factors compared between the two stocks.

About Tenax Therapeutics

Tenax Therapeutics, Inc. develops and commercializes pharmaceutical products containing imatinib for the treatment of pulmonary arterial hypertension in the United States. The company develops TNX-101 (IV), TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia. The company was formerly known as Oxygen Biotherapeutics, Inc. and changed its name to Tenax Therapeutics, Inc. in September 2014. Tenax Therapeutics, Inc. was founded in 1967 and is based in Chapel Hill, North Carolina.

About Biorestorative Therapies

BioRestorative Therapies, Inc., a life sciences company, focuses on the development of regenerative medicine products and therapies using cell and tissue protocols primarily involving adult stem cells. The company's two core developmental programs relate to the treatment of disc/spine disease and metabolic disorders. Its disc/spine program (brtxDisc) includes a lead cell therapy candidate, BRTX-100, a product candidate formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow, which has completed Phase 1 clinical trials for use in the non-surgical treatment of painful lumbosacral disc disorders. The company is also developing Metabolic Program (ThermoStem), a cell-based therapy candidate that is in preclinical stage to target obesity and metabolic disorders using brown adipose derived stem cells to generate brown adipose tissue. In addition, it provides investigational curved needle device designed to deliver cells and/or other therapeutic products or material to the spine and discs. BioRestorative Therapies, Inc. has a research and development agreement with Rohto Pharmaceutical Co., Ltd.; a research agreement with Pfizer, Inc.; and a research collaboration agreement with the University of Pennsylvania. The company was formerly known as Stem Cell Assurance, Inc. and changed its name to BioRestorative Therapies, Inc. in August 2011. The company was incorporated in 1997 and is based in Melville, New York.